Ana Vivancos

Has grant

Principal Investigator

Vall d'Hebron Institute of Oncology
Country flagSpain
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

CeLac and European consortium for a personalized medicine approach to Gastric Cancer-LEGACy

Open Date: 2019-01-01

Close Date: 2022-12-01

Grant: Close

Tumores primarios múltiples en pacientes con cáncer de pulmón: elaboración de un perfil molecular integral para elucidar orígenes genéticos comunes

Open Date: 2019-01-01

Close Date: 2023-01-01

Grant: Close

Measuring NRG1 mRNA levels by means of Nanostring at Vall d'Hebron

Open Date: 2019-01-01

Close Date: 2020-01-01

Grant: Close

Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GECJ)

Open Date: 2019-01-01

Close Date: 2026-01-01

Grant: Close

Biomarker testing NSG analysis

Open Date: 2019-01-01

Close Date: 2020-01-01

Articles (16)

Purpose: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer. Experimental Design: In this study, we utilized multiomics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions. Results: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared with their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved in genes within the same TAD, was associated with poor prognosis in estrogen receptor–positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes. Conclusions: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.

Year:

2026

Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.

Year:

2025

Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.

Year:

2025

Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.

Year:

2025

Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.

Year:

2025

Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.

Year:

2025

Tissue biomarker analyses and the VIGex score. A, Immune tumor contexture of the basal samples and surgical specimens in patients with MPR ( n = 8) and without MPR ( n = 25). B, Gene expression profile on surgical specimens, integrated within the VIGex score, and individual gene expression profile on surgical specimens. CK, cytokeratin; Post-ttm, posttreatment.

Year:

2025

Purpose: Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in earlier stages. In this study, we present the final results of the phase II MONEO trial, which evaluated the addition of avelumab to neoadjuvant chemotherapy. Patients and Methods: Patients with untreated, resectable G/GEJ adenocarcinoma received neoadjuvant treatment with four cycles of avelumab plus the FLOT4 regimen, followed by surgery. Upon postoperative recovery, patients underwent four additional adjuvant cycles of the same combination, followed by avelumab monotherapy for up to 1 year. The primary endpoint was pathologic complete response rate. Sequential flow cytometry and cytokine determination were performed in peripheral blood, along with multiplex tissue immunofluorescence and RNA sequencing in tumor specimens. Results: Forty patients were enrolled, achieving a pathologic complete response rate of 21.1% (95% confidence interval, 10.0–37.0). The major pathologic response rate was 28.9%, more pronounced in patients with tumors expressing PD-L1 before treatment as measured by the combined positive score (cutoff, 10; 33.3% vs. 21.1%). The results propose several potential biomarkers considering tumor immune infiltrate, circulating immune cells, and cytokines. Eighty percent of patients experienced treatment-related grade ≥3 adverse events. Conclusions: The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.

Year:

2025

Analyses on circulating cytokines and leukocytes. A, Mean difference in peripheral cytokines (fold change) at cycle 1, cycle 2, and at presurgery evaluation between patients with MPR ( n = 11) and without MPR ( n = 25). B, Peripheral immune cells quantified as percentages and compared baseline and posttreatment results showing the difference between pCR ( n = 3) and non-pCR ( n = 8) patients, with the delta in patients with pCR as indicated. Positive (green) or negative (red) differences are color-coded, and the magnitude is reflected by the intensity of the color. MDSC, myeloid-derived suppressor cell; PBM, peripheral blood mononuclear; PMN, polymorphonuclear; TR/EG, regulatory T cells.

Year:

2025

Efficacy endpoints. A, Percentage of tumor regression grade. B, Tumor regression grade depending on PD-L1 CPS, HER2, and MMR status. C, PFS. D, OS. E, Subgroup analysis for PFS. F, Subgroup analysis for OS. pMMR, MMR-proficient.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (50)

Maria Carmen Ochoa

Associate researcher

Center for Applied Medical Research

SPAIN
View details

Aaron R. Hansen

Medical Oncologist

University Health Network

CANADA
View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN
View details

SONIA PERNAS SIMON

Associate Professor

University of Barcelona

SPAIN
View details

Christos Sotiriou

Université libre de Bruxelles

BELGIUM
View details

Alena Gros

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Aleix Prat

Director Clínic Barcelona Comprehensive Cancer Centre (4C)

Hospital Clínic de Barcelona

SPAIN
View details

Albiruni R. Abdul Razak

University Health Network

CANADA
View details

Daniel Álvarez de la Sierra

Vall d'Hebron Research Institute

SPAIN
View details

Peter Katsikis

Professor & Head

Erasmus University Medical Center

NETHERLANDS
View details

Anthony Turpin

Centre Hospitalier Régional Universitaire de Lille

FRANCE
View details

Matteo Benelli

Head of Bioinformatics Unit

Azienda Usl Toscana Centro

ITALY
View details

Andrea Vingiani

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Raquel Perez-Lopez

Vall d'Hebron Institut de Recerca

SPAIN
View details

Joaquin Arribas

Research Director

Hospital del Mar

SPAIN
View details

Pamela S. Ohashi

University of Toronto

CANADA
View details

ENRIQUE JAVIER ARENAS LAHUERTA

Institute for Research in Biomedicine

SPAIN
View details

Jose A Seoane

Junior Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Hector Palmer

Director

Vall d'Hebron Institute of Oncology

SPAIN
View details

Winona Oliveros

KTH Royal Institute of Technology

SWEDEN
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Cindy Neuzillet

PU PH

Université de Versailles Saint-Quentin-en-Yvelines

FRANCE
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Philippe L. Bedard

University Health Network

CANADA
View details

Giuseppe Curigliano

European Institute of Oncology

ITALY
View details

Elisa Agostinetto

Institut Jules Bordet

BELGIUM
View details

Marta Mele

Group leader

Barcelona Supercomputing Center

SPAIN
View details

Oscar Pozo

Miguel Servet II

Institut Hospital del Mar d'Investigacions Mèdiques

SPAIN
View details

Roger Colobran

Head of Translational Immunology Research Group

Vall d'Hebron Institut de Recerca

SPAIN
View details

Ricardo Pujol Borrell

Universitat Autònoma de Barcelona (UAB)

SPAIN
View details

Elena Garralda

Director

-

SPAIN
View details

Mónica Martínez Gallo

Principal Researcher

Vall d'Hebron Institut de Recerca

SPAIN
View details

Guillermo Villacampa Javierre

Biostatistician

Vall d´Hebron Institute of Oncology

SPAIN
View details

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Clínic de Barcelona

SPAIN
View details

Paolo Nuciforo

Head

Vall d´Hebron Institut d´Oncologia

SPAIN
View details

Martin Espinosa-Bravo

Head of Breast Surgical Unit

-

SPAIN
View details

Concepción Violán

Seniror Researcher_Family Physisician

Institut Català de la Salut

SPAIN
View details

Manuel Hernandez-Gonzalez

Head of service

Hospital Universitari Vall d'Hebron

SPAIN
View details

Sandra Peiró

Head of the Chromatin Dynamics in Cancer Group

Vall d'Hebron Institute of Oncology

SPAIN
View details

Paula Jimenez-Fonseca

Central University Hospital of Asturias

SPAIN
View details

Manel Esteller

Group Leader, Cancer Epigenetics Group

Josep Carreras Leukaemia Research Institute

SPAIN
View details

Danai Fimereli

Université libre de Bruxelles (ULB)

BELGIUM
View details

Trevor J. Pugh

Professor

University Health Network

CANADA
View details

Cesar Serrano

External Group Leader (TRIP-Clinic program)

IRB Barcelona

SPAIN
View details

Gabriele Zoppoli

University of Genoa

ITALY
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Alex Sánchez-Pla

Professor

University of Barcelona

SPAIN
View details

Carlos E de Andrea

-

SPAIN
View details

Gloria Castillo

Vall d'Hebron Institute of Oncology

SPAIN
View details

TIAN TIAN

Vall d'Hebron Institute of Oncology

SPAIN
View details